| LY335979 |
|
| (CAS 167465-36-3) |
 |
| Description： |
LY335979(Zosuquidar) is a selective Pgp (P-glycoprotein) inhibitor with a Ki of 59 nM, and does not modulate MRP-mediated resistance by MRP1 (ABCC1) and MRP2 (ABCC2). LY335979 significantly enhanced the survival of mice implanted with Pgp-expressing murine leukemia (P388/ADR) when administered in combination with either daunorubicin, doxorubicin or etoposide. Coadministration of LY335979 with paclitaxel compared to paclitaxel alone significantly reduced the tumor mass of the Pgp-expressing UCLA-P3.003VLB lung carcinoma in a xenograph model. LY335979 was without significant effect on the pharmacokinetics of these anticancer agents.
|
| Product No. |
KT00536 |
| Product Name |
LY335979 |
| Synonyms |
RS 33295-198; Zosuquidar trihydrochloride |
| Formal Name |
|
| CAS Number |
167465-36-3 |
| Molecular Formula |
C32H31F2N3O2.3HCl |
| Formula Weight |
636.99 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
Dofequidar
Dofequidar fumarate
Elacridar
Tariquidar
Valspodar
Zosuquidar
|
|
